Showing 4641-4650 of 8214 results for "".
- Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://practicaldermatology.com/news/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2460641/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- DermOQ Oxygen Lab Completes Purchase of ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://practicaldermatology.com/news/dermoq-oxygen-lab-completes-purchase-of-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2460640/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2https://practicaldermatology.com/news/for-upper-facial-lines-daxibotulinumtoxina-succeeds-in-phase-2/2460637/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- Hydrafacial To Go Public After $1.1 Billion Dealhttps://practicaldermatology.com/news/hydrafacial-to-go-public-after-11-billion-deal/2460634/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Positive Topline Data from Phase 2b Study of Roflumilast Foam for Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-data-from-phase-2b-study-of-roflumilast-foam-for-scalp-and-body-psoriasis/2460633/Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, shared positive top line data from a Phase 2b clinical trial evaluating ARQ-
- FDA Defers Approval of Revance's Toxin Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://practicaldermatology.com/news/fda-defers-approval-of-revances-toxin-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2460628/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r
- Olay Body Teams Up with Olympic Snowboarder Jamie Anderson to Reduce Winter Skin Drynesshttps://practicaldermatology.com/news/olay-body-teams-up-with-olympic-snowboarder-jamie-anderson-to-reduce-winter-skin-dryness/2460626/Olay Body is teaming up with professional snowboarder and 2X Olympic gold medalist, Jamie Anderson, to give women the tools they need to combat the snow and freezing temperatures that take a toll on skin. Olay Body also joined forces with Oro Valley, Ariz-based dermatologist Sheil
- Colleen Goggins Joins ZO Skin Health's Board Of Directorshttps://practicaldermatology.com/news/colleen-goggins-joins-zo-skin-healths-board-of-directors-following-majority-investment-by-blackstone/2460624/Colleen Goggins is joining ZO Skin Health’s board of directors. This follows the recent acquisition of a majority stake in the business in October by funds managed by Blackstone Tactical Opportunities. As a partner and counsellor to a large variety of bu
- Dupixent Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe ADhttps://practicaldermatology.com/news/dupixent-approved-by-european-commission-as-first-and-only-biologic-medicine-for-children-aged-6-to-11-years-with-severe-ad/2460619/The European Commission (EC) has given its nod to Dupixent (dupilumab) for children 6 to 11 with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients. "As the parent
- Online Booking Functionality Comes to Demandforcehttps://practicaldermatology.com/news/online-booking-functionality-comes-to-demandforce/2460615/Demandforce has launched Demandforce Online Booking, a new functionality that makes it easier for clients of Demandforce business users to schedule appointments online while enabling businesses to manage their appointment sche